Journal article

Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.

S Welt, CR Divgi, N Kemeny, RD Finn, AM Scott, M Graham, JS Germain, EC Richards, SM Larson, HF Oettgen

Journal of Clinical Oncology | Published : 1994


PURPOSE: A phase I/II study was designed to determine the maximum-tolerated dose (MTD) of iodine 131-labeled monoclonal antibody (mAb) A33 (131I-mAb A33) administered intravenously, its limiting organ toxicity, and its radioisotope retention in tumors, and to develop preliminary evidence of antitumor activity. PATIENTS AND METHODS: Patients (N = 23) with colorectal cancer who had failed to respond to conventional chemotherapy but had not received prior radiotherapy were treated with escalating doses of 131I-mAb A33. Three or more patients were entered at each dose level, starting at 30 mCi/m2, with increments of 15 mCi/m2 to a maximal dose of 90 mCi/m2. Radiolabeling was performed to maintai..

View full abstract

University of Melbourne Researchers